IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

& Applicant:

Daniel E. Afar et al

Assignee:

UroGenesys, Inc.

Serial No.:

09/455,486

kaminer

NOV 09 2000

Filed:

December 6,

ODocket:

129.17USI1

TECH CENTER 1600/2809

Title:

RANSMEMBRANE ANTIGENS EXPRESSED IN NOVEL SERPEN

Group Art Unit:

HUMAN CANCERS AND USES THEREOF

CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on

Name: Karen S. Canady

REVOCATION AND POWER OF ATTORNEY

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Please revoke the existing Powers of Attorney, if any, and appoint the following attorneys and/or patent agents to prosecute this application and to transact all business in the U.S. Patent and Trademark Office in connection therewith:

George H. Gates

Registration No. 33,500

Victor G. Cooper

Registration No. 39,641

Karen S. Canady

Registration No. 39,927

William J. Wood Jason S. Feldmar

Registration No. 39,187

Registration No. 42,236

Please direct all correspondence in this application to Karen S. Canady at:

Gates & Cooper Howard Hughes Center 6701 Center Drive West, Suite 1050 Los Angeles, California 90045

Telephone: (310) 641-8797

Respectfully submitted,

UroGenesys, Inc.

Dated: 10 30/00

By: 499

AND DOWN THE REST OF THE REST OF MARKET THE PROPERTY.

to gain to property to the control of the state.

unity of billing till the mile to the term of the formation

Aya Jakobovits. Ph.D.

Vice President, Research

Chief Scientific Officer : कार्य कर्म कार्य

UroGenesys, Inc. Service States

1701 Colorado Avenue Santa Monica, CA 90404

**)

S/N 09/455,486

PATENT

IN THE UNITED STATES PATERT AND TRADEMARK OFFICE

RECEIVED

Applicant:

Daniel E. Afar et al.

Examiner:

Not yet assigned

NOV 09 2000

Serial No.:

09/455,486

Group Art Unit:

1643

TECH CENTER 1600/2800

Filed:

December 6, 1999

Docket:

G&C 129.17-US-I1

Title:

NOVEL SERPENTINE TRANSMEMBRANE ANTIGENS EXPRESSED IN

HUMAN CANCERS AND USES THEREOF

CERTIFICATE UNDER 37 C.F.R. § 3.73(b)

UROGENESYS, INC., a corporation organized and existing under the laws of the State of California, having a place of business at 1701 Colorado Avenue, Santa Monica, California 90404, certifies that it is the assignee of the entire right, title, and interest in the patent application identified above by virtue of:

An assignment from the inventor(s), Daniel E. Afar, Rene S. Hubert, Arthur B. Raitano, Douglas C. Saffran and Stephen C. Mitchell to UroGenesys, Inc., of the patent application identified above. A copy of the assignment is attached.

UroGenesys, Inc. owns 100% interest in the above-identified patent application.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, as the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: 1020/00

Name: Ava Jakobovita Ph.D.

Name: Aya Jakobovits, Ph.D.

Title: Vice President, Research
Chief Scientific Officer